Last reviewed · How we verify

NCT05416905: MEIGES

Deep Brain Stimulation for Idiopathic Craniofacial Dystonia: GPi or STN

Recruiting now NA Last updated 22 April 2025
What this trial tests

NA trial testing STN-DBS in Craniofacial Dystonia in 110 participants. Currently enrolling.

Timeline
22 June 2022
Primary endpoint
30 May 2025
30 May 2025

Quick facts

Lead sponsorBeijing Tiantan Hospital
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment110
Start date22 June 2022
Primary completion30 May 2025
Estimated completion30 May 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Beijing Tiantan Hospital

Who can join

Adults 18 to 75, any sex, with Craniofacial Dystonia or Deep Brain Stimulation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

MEIGES is a prospective, multicenter, randomized controlled clinical trial with the primary hypothesis that, STN-DBS is non-inferior to GPi-DBS for motor symptoms improvements at 365 days postoperatively in patients with idiopathic craniofacial dystonia.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Deep Brain Stimulation for the Management of Refractory Neurological Disorders: A Comprehensive Review.
    Rissardo JP, Vora NM, Tariq I, Mujtaba A, et al · · 2023 · cited 17× · PMID 38004040 · DOI 10.3390/medicina59111991

Verify or expand the search:

Other trials of STN-DBS

Trials testing the same drug.

Other recruiting trials for Craniofacial Dystonia

Currently open trials in the same condition.

Other Beijing Tiantan Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05416905.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing